ALLOTCBB Top Rated Top Upgraded Most Active Gainers Losers

0.0002 0 (0%)  01-02 13:43
Open: 0 Prev Close: 0.0002
High: 0 Low: 0
Volume: 0 Market Cap: 0M
Year High: 0.04 Year Low: 0
Stock Technical Analysis
Targets Six months: 0.0013    One year: 0.0021
Supports Support1:    Support2:
Resistances Resistance1: 0.0011    Resistance2: 0.0018 
Pivot Point 0.0010 
Moving Averages MA(5): 0.0001      MA(20): 0.0012 

MA(100): 0.0026  -1     MA(250):  
MACD MACD(12,26):       Signal(12,26,9):  
Stochastic Oscillator %K(14,3): 4.251      %D(3): 1.417 
RSI RSI(14): 16.135 
52-Week High: 0.0400  Low:   Change(%): -92
Average Volume(K) 3-Month: 47  10-Days: 3
Moving Averages analysis
Price and moving averages has closed below its Short term moving average. Short term moving average is below its mid-term; and below long term moving averages. From the relationship between price and moving averages; we can see that: this stock is BEARISH in short-term; and BEARISH in mid-long term.
Bollinger Bands Analysis
Bollinger Bands has closed above bottom band by 18.4%; Bollinger Bands are 12.1% narrower than normal.The current width of the bands does not suggest anything about the future direction or movement of prices.


Stock Chart

Top 100 stocks

Stock News
At the threshold of PhIII, Neurologix heads into bankruptcy
Mon, 19 Mar 2012 11:54:59 GMT

Vector Neurosciences LLC Offers Certain Assets Formerly Owned by Neurologix ...
Fri, 19 Feb 2016 12:45:00 GMT

Cerner, NeuroLogix Technologies to Integrate Tools to Advance Concussion Care
Mon, 24 Apr 2017 12:56:15 GMT

Ovid Therapeutics Continues Streak Of BioPharm Companies Going Public
Wed, 03 May 2017 12:56:15 GMT

POZEN Announces Strategic Acquisition of Tribute and Growth Capital Commitment ...
Mon, 08 Jun 2015 14:37:30 GMT

Gene therapy may be powerful new treatment for major depression
Wed, 20 Oct 2010 21:27:17 GMT

POZEN Announces Retirement of Founder, Chairman and CEO Dr. John R. Plachetka ...
Mon, 01 Jun 2015 10:52:30 GMT

Gene Therapy Reverses Symptoms of Parkinson's Disease
Wed, 16 Mar 2011 23:48:45 GMT

Retrophin: An Attractive Short Candidate Due To Numerous Red Flags
Wed, 28 May 2014 23:49:13 GMT

Newer Agents Effective in Parkinson's Disease Depression
Wed, 11 Apr 2012 20:55:33 GMT